Posters

The incidence and impact of pseudophakic cystoid macular oedema after phacoemulsification cataract surgery

Poster Details

First Author: C. da Costa Paula UNITED KINGDOM

Co Author(s):    M. Sulak   H. Sarwar   M. Watson              

Abstract Details

Purpose:

To investigate the incidence and impact of clinically significant pseudophakic cystoid macular oedema (pCMO) after cataract surgery.

Setting:

Moorfields Eye Hopsital, London, UK

Methods:

Retrospective review of clinical records from patients undergoing cataract surgery over a 6 month period from January to June 2014 at Moorfields Eye Hospital. By our definition of inclusion pCMO was considered to be a primary pathology only, meaning that eyes with worsening of preexisting macular oedema due to other causes (most commonly diabetic retinopathy, retinal vein occlusion, or uveitis) were not considered to have simple pCMO, but were considered to be a worsening of original pathology. Incidence, OCT image parameters, treatment protocols and visual outcomes were recorded and analyzed.

Results:

76 eyes (0.91%) developed simple pCMO. Most eyes (92%) have not received prophylactic topical NSAID drops in the postoperative period. On average the diagnosis of pCMO was made 5,8 (SD 4,48) weeks after the surgery and the average maximal retinal thickness at diagnosis was 436 (SD 122) microns. After a standard course of dexamethasone and topical NSAID, 75 eyes (98%) responded with complete resolution of pCMO and the average duration to resolution was 7,88 (SD3.34) weeks. The average visual acuity of eyes with pCMO was 0,57 (SD 0,58) logMAR preoperatively, then 0,41 (SD 0,24) logMAR during active pCMO, and finally 0,14 (SD 0,16) logMAR after complete resolution of pCMO.

Conclusions:

The incidence of pCMO after simple modern phacoemulsification cataract surgery is low, and 98% of eyes that do develop pCMO respond to a course of topical treatment alone with excellent final visual results. Prophylactic NSAID drops might be unnecessary in uncomplicated cataract surgery for eyes with no additional pathology.

Financial Disclosure:

NONE